Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings

A Prospective Non-interventional Study (Nis) Of The Routine Use Of Etanercept In The Long-term Treatment Of Patients With Plaque-type Psoriasis In Everyday Practice: An Efficacy, Safety, And Health Economic Evaluation

This prospective observational cohort study will assess the average duration of the drug free interval between etanercept treatment cycles in usual care settings in Germany.

Non-interventional study: subjects to be selected according to the usual clinical practice of their physician

Inclusion Criteria:

• Subjects with moderate to severe plaque psoriasis on etanercept treatment according to the Summary of Product Characteristics (SmPC), and applicable local guidelines
• Subjects for whom the decision has already been made to initiate treatment with etanercept

Exclusion Criteria:

• Sepsis or risk of sepsis
• Current or recent infections, including chronic or localized, e.g. tuberculosis (TB) infection
• Vaccination with live vaccine in last 4 weeks, or expected to require such vaccination during the course of the study
• Pre-existing or recent onset CNS demyelinating disease.
• Class III or IV congestive heart failure as defined by the New York Heart Association classification or uncompensated congestive heart failure.
• Previous or ongoing treatment with etanercept
• Participation in other clinical or observational studies.
• Patients with psoriatic arthritis requiring continuous etanercept treatment.